Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Schlioma Zaterka is active.

Publication


Featured researches published by Schlioma Zaterka.


Helicobacter | 2007

Factors Related to Helicobacter pylori Prevalence in an Adult Population in Brazil

Schlioma Zaterka; Jaime Natan Eisig; Decio Chinzon; Wolfgang P. Rothstein

Background:u2002 The prevalence of Helicobacter pylori is higher in developing countries. Sanitary facilities, crowding and ethnic group are some of the factors related to H. pylori infection. The aim of this study was to investigate in blood donors, free of dyspeptic symptoms, the prevalence and factors influencing H. pylori infection.


Arquivos De Gastroenterologia | 2018

IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION

Luiz Gonzaga Vaz Coelho; James Ramalho Marinho; Robert M. Genta; Laércio Tenório Ribeiro; Maria do Carmo Friche Passos; Schlioma Zaterka; Paulo Pimentel Assumpção; Alfredo José A Barbosa; Ricardo C. Barbuti; Lúcia Libanês Bessa Campelo Braga; Helenice Pankowski Breyer; Aloisio Carvalhaes; Decio Chinzon; Marcelo de Souza Cury; Gerson Domingues; Jorge Luiz Jorge; Ismael Maguilnik; Frederico Passos Marinho; Joaquim Prado de Moraes-Filho; José Miguel Luz Parente; Celso Mirra de Paula-E-Silva; José Pedrazzoli-Júnior; Ana Flávia Passos Ramos; Heinrich Seidler; José Nonato Spinelli; José Vitor Zir

Significant progress has been obtained since the III Brazilian Consensus Conference on H. pylori infection held in 2012, in Bento Gonçalves, Brazil, and justify a fourth meeting to establish updated guidelines on the current management of H. pylori infection. Therefore, the Núcleo Brasileiro para Estudo do Helicobacter pylori e Microbiota (NBEHPM), association linked to Brazilian Federation of Gastroenterology (FBG) held its fourth meeting again in Bento Gonçalves, RS, Brazil, on August 25-27, 2017. Twenty-six delegates, including gastroenterologists, endoscopists, and pathologists from the five regions of Brazil as well as one international guest from the United States, participated in the meeting. The participants were invited based on their knowledge and contribution to the study of H. pylori infection. The meeting sought to review different aspects of treatment for infection; establish a correlation between infection, dyspepsia, intestinal microbiota changes, and other disorders with a special emphasis on gastric cancer; and reassess the epidemiological and diagnostic aspects of H. pylori infection. Participants were allocated into four groups as follows: 1) Epidemiology and Diagnosis, 2) Dyspepsia, intestinal microbiota and other afections, 3) Gastric Cancer, and, 4) Treatment. Before the consensus meeting, participants received a topic to be discussed and prepared a document containing a recent literature review and statements that should be discussed and eventually modified during the face-to-face meeting. All statements were evaluated in two rounds of voting. Initially, each participant discussed the document and statements with his group for possible modifications and voting. Subsequently, during a second voting in a plenary session in the presence of all participants, the statements were voted upon and eventually modified. The participants could vote using five alternatives: 1) strongly agree; 2) partially agree; 3) undecided; 4) disagree; and 5) strongly disagree. The adopted consensus index was that 80% of the participants responded that they strongly or partially agreed with each statement. The recommendations reported are intended to provide the most current and relevant evidences to management of H. pylori infection in adult population in Brazil.


Arquivos De Gastroenterologia | 2003

Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole

Edson Pedro da Silva; Farid Nader; Flavio Quilici; Jaime Natan Eisig; Schlioma Zaterka; Ulysses G. Meneghelli

BACKGROUNDnEsomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis.nnnAIMnTo evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study.nnnMATERIAL AND METHODSnTwo hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug.nnnRESULTSnHealing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%).nnnCONCLUSIONnFor the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.


Digestion | 1974

Abstracts of the Research Forum of the Société Nationale Française de Gastroentérologie

S.R. Naik; S.C. Bajaj; R.K. Goyal; H.K. Chuttani; J.P.P. de Moraes-Filho; Schlioma Zaterka; Henrique Walter Pinotti; Agostinho Bettarello; A. Bennett; Jens F. Rehfeld; J. Allan; T.T. White; A. Stiehl; B. Rueff; J.N. Maillard; V. Wizemann; P. Weppler; R. Mahrt; Renato Dani; Lucyr Jones Antunes; José E.F. Ribeiro; Célio E. D Nogueira; Tarcísio Ribeiro; A.R. Cooke; M.G. Kienzle; T.J. Tubbesing; T.J. Morris; B.J. Calcraft; J. Rhodes; D. Hole


Arquivos De Gastroenterologia | 2001

Os anti-secretores alteram a distribuição do Helicobacter pylori no estômago

Schlioma Zaterka


Revista brasileira de medicina | 1998

ESTUDO CLINICO SOBRE A EFICACIA E A TOLERABILIDADE DE LANSOPRAZOL NO TRATAMENTO DA ULCERA DUODENAL

Schlioma Zaterka; A. F. Novaes De Magalhaes; Jaime Natan Eisig; A. A. Costa Leite Carvalhaes; Decio Chinzon


GED. Gastrenterologia endoscopia digestiva | 1998

Inibidores da bomba de protons (IBPs): tolerabilidade e seguranca

Schlioma Zaterka


RBM rev. bras. med | 1989

Ulcera duodenal refratária

Helena Keiko Massuda; Decio Chinzon; Jaime Natan Eisig; Schlioma Zaterka


GED gastroenterol. endosc. dig | 1984

Cafe e ulcera duodenal.

Jaime Natan Eisig; Schlioma Zaterka; H Masuda; J. M Zeitune; Agostinho Bettarello


GED gastroenterol. endosc. dig | 1982

Tratamento da ulcera peptica: do passado recente ao presente.

Schlioma Zaterka; Jaime Natan Eisig; Agostinho Bettarello

Collaboration


Dive into the Schlioma Zaterka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Decio Chinzon

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Célio E. D Nogueira

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

José E.F. Ribeiro

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar

Lucyr Jones Antunes

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar

Renato Dani

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar

Tarcísio Ribeiro

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar

A. Bennett

University of Cambridge

View shared research outputs
Researchain Logo
Decentralizing Knowledge